南美的醫療和醫藥品:市場與相關法規指南 是由出版商Urch Publishing, Ltd.在2011年09月所出版的。
這份英文市場調查報告書包含90 Pages 價格從美金2345起跳。
南美對製藥公司來說是一大商機，到2020年為止人口將達到6億8,700萬人，醫藥品產業的基本客群將擴大。南美的醫藥品市場規模現在為450億美元，跨國公司特別關注巴西和墨西哥。
本報告提供南美19個國家醫療制度概要，各國的醫藥品市場，相關法規概要，國內市場學名藥所扮演的角色等驗證，為您概述為以下內容。
摘要整理
第1章 南美的特徵
- 南美的特徵
- 對南美的投資
- 南美中政治趨勢的變化
- 南美的政策與醫療
- 美國州機關
第2章 南美的醫療環境
- 南美的醫療政策方法
- 人口趨勢
- 南美的醫療制度改革對醫藥品產業的影響
- 南美的醫藥品市場
- 南美和仿製藥
- 智慧財產權
- 主要的醫藥品
- 強制授權
- 臨床實驗
第3章 阿根廷:醫療和醫藥品
- 醫療制度
- 醫藥品市場
- 醫藥品產業
- 相關法規
- 相關案例研究:投資阿根廷仿製藥的印度製藥公司
- 智慧財產權問題
第4章 貝里斯
第5章 玻利維亞
第6章 巴西
- 醫療制度
- 醫藥品市場
- 國內醫藥品產業
- 相關法規
- 學名藥
- 智慧財產權
- 臨床實驗
- 獲得醫療保健
第7章 智利
第8章 哥倫比亞
第9章 哥斯大黎加
第10章 厄瓜多
第11章 薩爾瓦多
第12章 瓜地馬拉
第13章 宏都拉斯
第14章 墨西哥
第15章 尼加拉瓜
第16章 巴拿馬
第17章 巴拉圭
第18章 秘魯
第19章 烏拉圭
第20章 委內瑞拉
圖表
Abstract
Summary
Although Latin America offers substantial business opportunities for
companies, it is a volatile region in economic terms. There is considerable
risk involved in investing in the region and companies need to be fully aware
of past economic crises and their causes before becoming involved. Latin
America continues to be a region of promising opportunities for commercial
pharmaceutical organisations. The region represents a growing consumer base
for the drug industry as by 2020 the regional population may be as high as 687
million.
The Latin American pharmaceutical market is now worth $45bn and multinational
companies consider success in Brazil and Mexico as essential.
Healthcare & Pharmaceuticals in Latin America - A guide to the markets
and regulations provides an excellent overview of the healthcare and
pharmaceutical market in 19 Latin American countries.
This 40,000 word report, from URCH Publishing, will provide the reader with an
excellent review of the healthcare systems, politics, regulatory framework,
major companies and key issues affecting the healthcare sector.
Some of the main issues concerning pharmaceutical companies operating in the
region include:
Intellectual Property: Laws on intellectual property remain weak or are not
enforced in a number of countries, leading legally ambiguous products on the
market.
Generics: Regional governments are making serious attempts to encourage the
use of generics (in the past the term bioequivalence was interpreted differing
across countries) and Indian companies in particular have made headway into
the major markets.
R&D: Companies are finding Latin America an attractive centre for R&D. There
are currently an estimate 4,000 clinical trials being conducted. High
enrolment rates, lower labour costs and improving regulation have estimated
the growth in outsourcing.
Political Situation: Unsettling for multinational companies is the political
shift to the left in some countries. However, a number of countries are
working to introduce universal healthcare coverage which in turn could create
excellent long term opportunities.
Key features of the report:
- Overview of healthcare systems in 19 Latin American countries
- Review of the pharmaceutical market and major companies operating in each
country
- Brief guide to the relevant regulatory structure with comment on
intellectual property issues.
- Evaluation of the role of the generics in the domestic market
This report can help you:
- Review the key political and government structures that influence business
in the region
- Understand the distinct characteristics of the Latin American
pharmaceutical market
- Consider how increased democracy will affect healthcare systems in
relation to inequality and essential medicines
- Gain insight into how generics are being promoted by a number of
governments
- Plan market strategy for successful entry and operation in the region
Countries Covered:
Argentina - Belize - Bolivia - Brazil - Chile - Colombia - Costa Rica - Costa
Rica - Ecuador - El Salvador - Guatemala - Honduras - Mexico - Nicaragua -
Panama - Paraguay - Peru - Uruguay - Venezuela
Table of Contents
Executive Summary
Chapter 1: Characteristics of Latin America
- Characterising Latin America
- Investment in Latin America
- The changing political situation in Latin America
- Politics and healthcare in Latin America
- The Organization of American States
- The North American Free Trade Agreement
- Central America-United States Free Trade Agreement
- Mercosur
- The Andean community
- La Asociacion Latinoamericana de Integracion
- The Pan American Health Organization
- Latin American Pharmaceutical Industry Association
Chapter 2: The Latin American healthcare environment
- Approach to Latin American healthcare policy
- Population trends
- Implications of Latin American healthcare reform for the pharmaceutical
industry
- The Latin American pharmaceutical markets
- Latin America and generics
- Intellectual property
- Case study: Pfizer in Latin America
- Essential medicines
- Compulsory licensing
- Clinical trials
Chapter 3: Argentina - Healthcare & Pharmaceuticals
- Healthcare system
- The pharmaceutical market
- The pharmaceutical industry
- Regulatory
- Case study: Indian pharmaceutical companies invest in Argentina
- Generics
- Intellectual property issues
- Case study: The pharmaceutical black market in Argentina
- Clinical trials
- Case study: La Sociedad Argentina de Investigacion Clinica
Chapter 4: Belize
- Healthcare system
- Pharmaceutical market
Chapter 5: Bolivia
- Healthcare system
- Pharmaceutical market
- Regulations
Chapter 6: Brazil
- Healthcare system
- The pharmaceutical market
- The domestic pharmaceutical industry
- Case study: UNAIDS and Brazil launch joint initiative to counter AIDS in
developing nations
- Regulatory
- Generics
- Intellectual property
- Clinical trials
- Access to medicines
Chapter 7: Chile
- Healthcare system
- The pharmaceutical market
- The pharmaceutical industry
- Generics
- Regulatory
- Clinical trials
Chapter 8: Colombia
- Healthcare system
- The pharmaceutical market
- The pharmaceutical industry
- Intellectual property issues
- Generics
- Regulatory
- Clinical trials
Chapter 9: Costa Rica
- Healthcare system
- Pharmaceutical market
- Pricing
- Regulations
- Intellectual property
- Case study: Abbott battles Indian generics manufacturer in Costa Rica
Chapter 10: Ecuador
- Healthcare system
- Pharmaceutical market
- Intellectual property
Chapter 11: El Salvador
- Healthcare system
- Pharmaceutical market
- Generics
Chapter 12: Guatemala
- Healthcare system
- Pharmaceutical market
- Generics
- Intellectual property issues
Chapter 13: Honduras
- Healthcare system
- Pharmaceutical market
Chapter 14: Mexico
- Healthcare system
- The pharmaceutical market
- Generics
- Similares
- Pharmaceutical supply
- Multinational pharmaceutical company presence
- Clinical trials
- Intellectual property issues
- Case study: Cross border purchasing of pharmaceuticals in Mexico
- Case study: Drug counterfeiting in Mexico
- Illegal drug importation
Chapter 15: Nicaragua
- Healthcare system
- Pharmaceutical market
Chapter 16: Panama
- Healthcare system
- Pharmaceutical market
Chapter 17: Paraguay
- Healthcare system
- Pharmaceutical market
- Pricing
- Regulatory
- Intellectual property
Chapter 18: Peru
- Healthcare system
- Pharmaceutical market
- Pricing
- Generics
- Regulations
- Clinical trials
Chapter 19: Uruguay
- Healthcare system
- Pharmaceutical market
- Regulatory
- Pricing
- Case study: Pharmaceutical companies accused of abuse of dominant
position in Uruguay
Chapter 20: Venezuela
- Healthcare system
- Pharmaceutical market
- Case study: Pfizer Venezuela
- Generics
- Intellectual property issues
- Counterfeits
- About URCH Publishing
List of Figures
- Figure 1.1: Gross national income per capita (PPP international $)
- Figure 1.2: Healthcare spending as percent of GDP
- Figure 1.3: Life expectancy in Latin America (by country)
- Figure 2.1: Latin America - population growth
- Figure 2.2: Latin American pharmaceutical market split (2011)
- Figure 2.3: Leading pharmaceutical markets in Latin America (2011)
- Figure 2.4: Emerging pharmaceutical markets in Latin America (2011)
- Figure 2.5: Regional split of Phase III clinical trials (2011)
- Figure 3.1: Density of the Health Workforce in Argentina
- Figure 6.1: Phase III trials by Country (2011)
- Figure 6.2: Phase II trials by Country (2011)
- Figure 7.1: Pharmaceutical Market in Chile
- Figure 8.1: Growth of Colombian Pharmaceutical Market
- Figure 9.1: Costa Rica: Pharmaceutical imports by country
- Figure 9.2: Costa Rica: Pharmaceutical exports by country
- Figure 12.1: Innovator versus Generic Price Class Comparison in Guatemala
- Figure 14.1: Employment in the Mexican Pharmaceutical Industry
- Figure 14.2: Share of Mexican Pharmaceutical Market
- Figure 18.1: Leading causes of mortality in Peru
- Figure 18.2: Mortality rate for communicable diseases in Peru
- Figure 19.1: Uruguayan pharmaceutical sector exports
- Figure 19.2: Uruguayan pharmaceutical sector imports
List of Tables
- Table 1.1: Member countries of the OAS
- Table 2.1: Ranbaxy in Latin America
- Table 6.1: ANVISA regulations
- Table 14.1: Pharmaceutical product types in Mexico
